The community of Mt. Washington came together Tuesday to support pediatric cancer patients and survivors. Seth’s Squad hosted its fifth annual blood drive, Rise of the Donor, in collaboration with the ...

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

Mabry was a toddler when her local doctors realized her best chance at survival would be St. Jude Children’s Research ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

To know 8-year-old Brielle Ambabo is to love her. Her silly personality, upbeat attitude and countless jokes are sure to ...

Brunswick High School's "Brunswick for a Brighter Future" Student Visionaries team raised $168,000 for the Leukemia & ...

Sana revolutionizes treatments for diabetes, cancer, and autoimmune diseases. SANA has high cash burn and dilution risks. See ...

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.

Researchers sought to determine whether using HRD sources for HSCT would be effective for pediatric patients with hematologic cancers compared with UCB sources.

"Run in Yellow" is an initiative to raise funds for children battling cancer, in collaboration with the Tijuana General Hospital.

The family of a Perth teenager who is battling a sixth relapse of leukaemia are desperately trying to fund potentially ...

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus recommendation of “Hold” from the twenty-four ...